National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 4) (No. PB 31 of 2014) (Cth)

PB 31 of 2014

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 4)

National Health Act 1953

___________________________________________________________________________

I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated   15 April 2014

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Principal Pharmacy Advisor  

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________

1              Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.4).

(2)This Instrument may also be cited as PB 31 of 2014.

2             Commencement

This Instrument commences on 1 May 2014.

3              Amendments to PB 79 of 2011

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1                   Amendments

1. Schedule 1 Part 1, entry for Docetaxel in the form ‘Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent’ with manner of administration Injection:

omit:     

Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent Injection AS-Docetaxel YA MP C3888 C3892 C3916 C3956 C4078 C4140 C4160 C4239 D

1. Schedule 1 Part 1, after the entry for Doxorubicin in the form ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial’ with manner of administration Injection/intravesical and brand ‘Doxorubicin Ebewe’:

insert:    

Doxorubicin MYX YN MP D

1. Schedule 3, Responsible Person codes, after entry for YA:

insert:

YN Mayne Pharma International Pty Ltd  88 007 870 984